Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies

Area of Science:

• Oncology
• Pharmacology

Background:

• Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is approved for B-cell malignancies like Waldenström macroglobulinemia (WM) and chronic lymphocytic leukemia (CLL).
• Off-target effects such as atrial fibrillation, hypertension, and bleeding can limit patient tolerance to ibrutinib treatment.
• No established guidelines exist for managing patients who cannot tolerate ibrutinib.

Approach:

• Literature review to identify and synthesize current management strategies for ibrutinib-intolerant patients.
• Analysis of treatment options including supportive care, dose modification, switching to alternative BTK inhibitors, or alternative therapies.
• Guidance development for clinicians treating B-cell malignancy patients experiencing ibrutinib intolerance.

Key Points:

• Managing ibrutinib intolerance involves supportive care, dose reduction, or switching to other BTK inhibitors.
• Alternative treatments may be necessary for patients unable to tolerate covalent BTK inhibitors.
• This review provides a framework for clinical decision-making in ibrutinib-intolerant patients.

Conclusions:

• Effective management strategies are crucial for patients with B-cell malignancies who develop intolerance to ibrutinib.
• The review offers practical guidance for optimizing treatment in this patient population.
• Further research may be needed to establish definitive treatment algorithms for ibrutinib intolerance.